Characterize Cancer: Tissue Profiling¹
741 genes for expanded genotyping
47 promoter methylation genes
RNA-based fusion detection for a comprehensive view of
common and rare fusions and splice isoforms
Guardant Infinity is for research use only. Not for diagnostic purposes.
Important note: Guardant360 Liquid was developed as a Laboratory Developed Test (LDT), and its performance characteristics determined, by the Guardant Health Clinical Laboratory in Redwood City, CA, USA, which is certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA) as qualified to perform high-complexity clinical testing. This test has not been cleared or approved by the US FDA. Guardant Hereditary Cancer was developed as an LDT and is not cleared or approved by the US FDA.
CHARACTERIZE CANCER
Profile tumors to reveal current and emerging cancer biomarkers with our cutting-edge technology.
Characterize Cancer: Liquid Profiling¹
755 genes for expanded genotyping
Methylation-based tumor fraction to quantify disease burden
Home Guardant Infinity™ for BioPharma Guardant360® CDx for BioPharma GuardantINFORM for BioPharma